Editas Medicine, Inc.
$3.57
▲
2.3%
2026-04-21 06:33:02
www.editasmedicine.com
NMS: EDIT
Explore Editas Medicine, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$349.4 M
Current Price
$3.57
52W High / Low
$4.54 / $1.23
Stock P/E
—
Book Value
$0.28
Dividend Yield
—
ROCE
-70.81%
ROE
-1.98%
Face Value
—
EPS
$-1.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
87
Beta
2.04
Debt / Equity
66.34
Current Ratio
3.54
Quick Ratio
3.54
Forward P/E
-3.41
Price / Sales
7.1
Enterprise Value
$159.2 M
EV / EBITDA
-1.69
EV / Revenue
3.93
Rating
Buy
Target Price
$5.5
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AEON Biopharma, Inc. | $1.07 | — | $25.81 M | — | 252.78% | -46.26% | $1.45 / $0.38 | $-4.54 |
| 2. | Precision BioSciences, Inc. | $7.58 | — | $187.43 M | — | -35.84% | -62.71% | $8.82 / $3.53 | $3.83 |
| 3. | Fate Therapeutics, Inc. | $1.39 | — | $158.12 M | — | -52.22% | -51.84% | $1.94 / $0.91 | $1.8 |
| 4. | Acumen Pharmaceuticals, Inc. | $2.84 | — | $203.64 M | — | -133.4% | -96.2% | $3.6 / $0.85 | $1.16 |
| 5. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 6. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 7. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 24.74 M | 7.54 M | 3.58 M | 4.66 M | 30.6 M | — |
| Operating Profit | -14.02 M | -24.55 M | -25.46 M | -35.31 M | -34.36 M | — |
| Net Profit | -5.62 M | -25.12 M | -53.23 M | -76.09 M | -45.4 M | — |
| EPS in Rs | -0.06 | -0.26 | -0.54 | -0.78 | -0.46 | -0.75 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 40.52 M | 32.31 M | 78.12 M | 19.71 M |
| Operating Profit | -99.34 M | -238.92 M | -169.18 M | -225.95 M |
| Net Profit | -160.06 M | -237.09 M | -153.22 M | -220.43 M |
| EPS in Rs | -1.64 | -2.42 | -1.57 | -2.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 186.53 M | 341.59 M | 499.15 M | 514.32 M |
| Total Liabilities | 159.25 M | 207.31 M | 150.06 M | 153.64 M |
| Equity | 27.29 M | 134.27 M | 349.1 M | 360.68 M |
| Current Assets | 163.9 M | 289.31 M | 340.83 M | 356.75 M |
| Current Liabilities | 46.25 M | 77.22 M | 63.22 M | 60.11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -165.24 M | -210.28 M | -132.18 M | -177.35 M |
| Investing CF | 138.67 M | 162.15 M | -3.73 M | 114.07 M |
| Financing CF | 40.47 M | 56.03 M | 118.04 M | 1.28 M |
| Free CF | -165.85 M | -219.11 M | -136.9 M | -181.47 M |
| Capex | -0.61 M | -8.83 M | -4.72 M | -4.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -58.64% | 296.32% | — | — |
| Earnings Growth % | -54.74% | 30.49% | — | — |
| Profit Margin % | -733.72% | -196.13% | -1118.26% | — |
| Operating Margin % | -739.37% | -216.56% | -1146.26% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -708.96% | -208.8% | -1114.11% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.